var data={"title":"Mecasermin (recombinant human insulin-like growth factor I): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mecasermin (recombinant human insulin-like growth factor I): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/85869?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mecasermin-recombinant-human-insulin-like-growth-factor-i-drug-information\" class=\"drug drug_general\">see &quot;Mecasermin (recombinant human insulin-like growth factor I): Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618073\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Increlex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16159984\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Growth Hormone</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16159991\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mecasermin-recombinant-human-insulin-like-growth-factor-i-drug-information\" class=\"drug drug_general\">see &quot;Mecasermin (recombinant human insulin-like growth factor I): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary IGFD: </b> Increlex: Children &ge;2 years and Adolescents: SubQ: Initial: 0.04 to 0.08 mg/kg/dose twice daily; if tolerated for 7 days, may increase by 0.04 mg/kg/dose; maximum dose: 0.12 mg/kg/dose twice daily. <b>Note:</b> Must be administered within 20 minutes of a meal or snack; omit dose if patient is unable to eat. Reduce dose if hypoglycemia occurs despite adequate food intake; dose should not be increased to make up for &ge;1 omitted dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> Children &ge;2 years and Adolescents: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Children &ge;2 years and Adolescents: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; has not been studied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618332\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Increlex: 40 mg/4 mL (4 mL) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618075\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16159992\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Must be administered within 20 minutes of a meal or snack. May cause hypoglycemic effects; patients should avoid high-risk activities within 2-3 hours of dosing until a tolerated dose is established. If patient is unable to eat, omit dose and do not make up for omitted dose. Rotate injection site (upper arm, thigh, buttock, abdomen) to help prevent lipohypertrophy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618317\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Store vials under refrigeration at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); keep refrigerated and use within 30 days of initial vial entry. Do not freeze. Protect from direct light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16159985\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (IGF-1 deficiency; primary IGFD), or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH (FDA approved in children &ge;2 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618312\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Heart murmur</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoglycemia, lipohypertrophy (injection site), thymus hypertrophy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Bruising at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, limb pain, muscular atrophy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Abnormal tympanometry, fluid in ear (middle ear), hypoacusis, otalgia, otitis media, serous otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Snoring, tonsillar hypertrophy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, cardiomegaly, heart valve disease, hypercholesterolemia, hypersensitivity, hypertriglyceridemia, hypoglycemic seizure, increased lactate dehydrogenase, increased serum ALT, increased serum AST, intracranial hypertension, obstructive sleep apnea syndrome, osteonecrosis (occasionally associated with slipped capital femoral epiphysis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618080\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to mecasermin or any component of the formulation; patients with closed epiphyses; active or suspected neoplasia; intravenous administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618081\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (localized skin reactions to anaphylaxis) have been reported. If hypersensitivity is suspected; discontinue and instruct patient to seek immediate medical attention. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypoglycemia: May cause hypoglycemic effects, especially in small children (due to inconsistent oral intake); patients should avoid high-risk activities (eg, driving) within 2 to 3 hours after dosing, particularly at initiation of treatment, until a tolerated dose is established. Do not administer on days a patient cannot or will not eat. Should be administered with a meal or a snack.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intracranial hypertension: Intracranial hypertension with headache, nausea, papilledema, visual changes, and/or vomiting has been reported with growth hormone product; funduscopic examinations are recommended at initiation of therapy and periodically thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lymphoid hypertrophy: Has been reported and may lead to complications such as snoring, sleep apnea, and chronic middle-ear effusions. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Slipped capital femoral epiphyses: Patients with growth hormone deficiency can develop slipped capital femoral epiphyses more frequently; evaluate any child with new onset of a limp or with complaints of hip or knee pain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes or with risk factors for glucose intolerance; may decrease insulin sensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Scoliosis: Progression of scoliosis may occur in children experiencing rapid growth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Correct thyroid or nutritional deficiencies prior to therapy. Not intended for use in patients with secondary forms of IGF-1 deficiency (GH deficiency, malnutrition, hypothyroidism, chronic anti-inflammatory steroid therapy). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299652\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221491\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88323&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Growth Hormone Products may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618077\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618078\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal studies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16159993\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Preprandial glucose during treatment initiation and dose adjustment; hypersensitivity reactions; facial features; lymphoid tissue; funduscopic examination (at initiation and periodically thereafter); growth; new onset of a limp or complaints of hip or knee pain; progression of scoliosis. Monitor small children closely due to potentially erratic food intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16159994\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe primary IGFD is defined as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Height standard deviation score &le; -3.0 <b>and</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Basal IGF-1 standard deviation score &le; -3.0 <b>and</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Growth hormone: Normal or increased</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618318\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Mecasermin is an insulin-like growth factor (IGF-1) produced using recombinant DNA technology to replace endogenous IGF-1. Endogenous IGF-1 circulates predominately bound to insulin-like growth factor-binding protein-3 (IGFBP-3) and a growth hormone-dependent acid-labile subunit (ALS). Acting at receptors in the liver and other tissues, endogenous growth hormone (GH) stimulates the synthesis and secretion of IGF-1. In patients with primary severe IGF-1 deficiency, growth hormone receptors in the liver are unresponsive to GH, leading to reduced endogenous IGF-I concentrations and decreased growth (skeletal, cell, and organ). Endogenous IGF-1 also suppresses liver glucose production, stimulates peripheral glucose utilization, and has an inhibitory effect on insulin secretion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1618321\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Severe primary insulin-like growth factor-1 deficiency (IGFD): 0.257 (&plusmn; 0.073) L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;80% bound to IGFBP-3 and an acid-labile subunit (IGFBP-3 reduced with severe primary IGFD)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and renal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 100% (healthy subjects)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Severe primary IGFD: ~5.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak serum concentration: 2 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160023\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If using syringes that measure dose in units, doses in mg/kg must be converted to units using the following formula: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight (kg) &times; Dose (mg/kg) &times; 1 mL/10 mg &times; 100 units/1 mL = units/injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322875\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Increlex Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/4 mL (4 mL): $4,873.19</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992803\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Increlex (AT, BB, BE, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HR, HU, IE, IL, IT, LT, LU, LV, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mecasermin-recombinant-human-insulin-like-growth-factor-i-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mecasermin-recombinant-human-insulin-like-growth-factor-i-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Backeljauw PF, Underwood LE, and GHIS Collaborative Group, &quot;Therapy for 6.5-7.5 Years With Recombinant Insulin-Like Growth Factor I in Children With Growth Hormone Insensitivity Syndrome: A Clinical Research Center Study Syndrome,&quot; <i>J Clin Endocrinol Metab</i>, 2001,  86(4):1504-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mecasermin-recombinant-human-insulin-like-growth-factor-i-pediatric-drug-information/abstract-text/11297575/pubmed\" target=\"_blank\" id=\"11297575\">11297575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mecasermin-recombinant-human-insulin-like-growth-factor-i-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Increlex (mecasermin) [prescribing informaiton]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metz KA, Assa'ad A, Lierl MB, et al, &ldquo;Allergic Reaction to Mecasermin,&rdquo; <i>Ann Allergy Asthma Immunol</i>, 2009, 103(1):82-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mecasermin-recombinant-human-insulin-like-growth-factor-i-pediatric-drug-information/abstract-text/19663134/pubmed\" target=\"_blank\" id=\"19663134\">19663134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torjusen E, Calderon J, and Rivkees SA, &ldquo;Anaphylactic Reaction to Recombinant Insulin-Like Growth Factor-I,&rdquo; <i>J Pediatr Endocrinol Metab</i>, 2008, 21(4):381-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mecasermin-recombinant-human-insulin-like-growth-factor-i-pediatric-drug-information/abstract-text/18556970/pubmed\" target=\"_blank\" id=\"18556970\">18556970</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88323 Version 54.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F1618073\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F16159984\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F16159991\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F1618332\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F1618075\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16159992\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F1618317\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16159985\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F1618312\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F1618080\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F1618081\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299652\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221491\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F1618077\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1618078\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16159993\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F16159994\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F1618318\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F1618321\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F16160023\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322875\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992803\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/88323|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mecasermin-recombinant-human-insulin-like-growth-factor-i-drug-information\" class=\"drug drug_general\">Mecasermin (recombinant human insulin-like growth factor I): Drug information</a></li></ul></div></div>","javascript":null}